Ir directamente a la navegación principal Ir directamente a la búsqueda Ir directamente al contenido principal

Estimating Socio-Economic Status for Alzheimer’s Disease Trials

  • Dorene M. Rentz
  • , J. D. Grill
  • , D. P. Molina-Henry
  • , G. A. Jicha
  • , M. S. Rafii
  • , A. Liu
  • , R. A. Sperling
  • , P. S. Aisen
  • , R. Raman

Producción científica: Articlerevisión exhaustiva

2 Citas (Scopus)

Resumen

Introduction: Metrics of a participant’s socioeconomic status (SES) are not routinely collected or standardized in clinical trials. This omission limits the ability to evaluate the generalizability of trial results and restricts clinicians from confidently interpreting the efficacy of new treatments across important sub-populations. Methods: We adapted an SES measure of social disparity; the Hollingshead Two Factor Index of Social Position, which combines education and occupation into a single metric. We modernized the 1965 occupations to reflect the 2017 careers tabulated by the US Bureau of Labor Statistics. We currently use this adapted measure in Alzheimer’s Clinical Trials Consortium studies. Results: We present the revised table of occupations. We found that the collection of SES data using the modified Hollingshead was feasible in a multi-site clinical trial and scores were distributed across all SES strata. Discussion: The modified Hollingshead provides a standardized method for collecting SES information, enabling data aggregation, monitoring, and reporting.

Idioma originalEnglish
Páginas (desde-hasta)1418-1425
Número de páginas8
PublicaciónJournal of Prevention of Alzheimer's Disease
Volumen11
N.º5
DOI
EstadoPublished - oct 2024

Nota bibliográfica

Publisher Copyright:
© The Authors 2024.

Financiación

The authors would like to thank the site principal investigators of AHEAD study along with their staff, participants and their study partners. We also thank the Alzheimer Therapeutic Research Institute (ATRI) and the Alzheimer Clinical Trial Consortium for making this data available. Funding: The Alzheimer’s Clinical Trials Consortium (ACTC) is supported through funding provided by the National Institute on Aging (U24AG057437). The AHEAD Study is conducted as a Public-Private Partnership of the Alzheimer’s Clinical Trial Consortium (ACTC), funded by the National Institute on Aging (R01AG061848, R01AG054029), Eisai Inc., the GHR Foundation and other philanthropists.

FinanciadoresNúmero del financiador
Alzheimer Clinical Trial Consortium
Alzheimer Therapeutic Research Institute
GHR Foundation
Eisai Incorporated
National Institute on AgingU24AG057437
National Institute on Aging
Alzheimer’s Clinical Trial ConsortiumR01AG054029, R01AG061848

    ODS de las Naciones Unidas

    Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

    1. Good health and well being
      Good health and well being

    ASJC Scopus subject areas

    • Clinical Neurology
    • Psychiatry and Mental health

    Huella

    Profundice en los temas de investigación de 'Estimating Socio-Economic Status for Alzheimer’s Disease Trials'. En conjunto forman una huella única.

    Citar esto